The impact of oral exposure to low-dose tris(2-butoxyethyl) phosphate in allergic asthmatic mice.
Rie YanagisawaEiko KoikeTin-Tin Win-ShweMaiko KawaguchiHirohisa TakanoPublished in: Journal of applied toxicology : JAT (2020)
Tris(2-butoxyethyl) phosphate (TBEP) is a major organophosphorus flame retardant and has been widely increasing as a substitute for brominated flame retardants. TBEP may have adverse effects on human health; however, its impact on immune and allergic responses remains largely uncharacterized. In this study, the effects of low-dose TBEP comparable with the level of actual human exposure to that of human tolerable daily intake on allergic asthmatic mice were explored. Five-week-old C3H/HeJSlc male mice consumed a diet containing approximately 0.02, 0.2 or 2 μg/kg/day TBEP and were intratracheally administrated ovalbumin (OVA) (1 μg/mouse every 2 weeks from 5 to 11 weeks of age). Exposure to 2 μg/kg/day TBEP with OVA tended to enhance allergic pulmonary inflammation and significantly elevated mRNA levels of interleukin-5, eotaxin-1 and estrogen receptor alpha (ERα) compared with OVA alone. In mediastinal lymph nodes (MLNs), TBEP (0.2 or 2 μg/kg/day) with OVA significantly increased in total cell number and promoted conventional dendritic cell activation than OVA alone; MLN cell proliferation by OVA restimulation was also enhanced in these groups. In the bone marrow (BM), TBEP (0.02 or 0.2 μg/kg/day) with OVA resulted in a net decrease in total cell number and fraction of CCR2+ Gr-1+ cells; the fraction of Gr-1+ cells increased. In conclusion, oral exposure to low-dose TBEP levels equivalent to tolerable daily intake may exacerbate allergic pulmonary inflammation by promoting a skewed T-helper 2 cell response, upregulation of ERα and dysregulation of both MLN and BM microenvironments.
Keyphrases
- low dose
- estrogen receptor
- dendritic cells
- cell proliferation
- lymph node
- induced apoptosis
- single cell
- endothelial cells
- bone marrow
- human health
- allergic rhinitis
- physical activity
- cell therapy
- oxidative stress
- risk assessment
- high dose
- pulmonary hypertension
- regulatory t cells
- cell cycle arrest
- type diabetes
- randomized controlled trial
- atopic dermatitis
- weight loss
- poor prognosis
- cell cycle
- signaling pathway
- stem cells
- weight gain
- mesenchymal stem cells
- body mass index
- metabolic syndrome
- climate change
- high resolution
- neoadjuvant chemotherapy
- mass spectrometry
- insulin resistance
- breast cancer cells
- preterm birth
- long non coding rna
- locally advanced
- double blind
- gas chromatography